These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31754711)

  • 21. Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.
    Shen W; De Hoyos CL; Sun H; Vickers TA; Liang XH; Crooke ST
    Nucleic Acids Res; 2018 Mar; 46(5):2204-2217. PubMed ID: 29390093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo.
    Prakash TP; Johnston JF; Graham MJ; Condon TP; Manoharan M
    Nucleic Acids Res; 2004; 32(2):828-33. PubMed ID: 14762210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides.
    Anderson BA; Freestone GC; Low A; De-Hoyos CL; Iii WJD; Østergaard ME; Migawa MT; Fazio M; Wan WB; Berdeja A; Scandalis E; Burel SA; Vickers TA; Crooke ST; Swayze EE; Liang X; Seth PP
    Nucleic Acids Res; 2021 Sep; 49(16):9026-9041. PubMed ID: 34417625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Phosphorus and Non-Phosphorus Neutral Oligonucleotide Backbones for Enhancing Therapeutic Index of Gapmer Antisense Oligonucleotides.
    Vasquez G; Migawa MT; Wan WB; Low A; Tanowitz M; Swayze EE; Seth PP
    Nucleic Acid Ther; 2022 Feb; 32(1):40-50. PubMed ID: 34698585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solid-Phase Synthesis of Boranophosphate/Phosphorothioate/Phosphate Chimeric Oligonucleotides and Their Potential as Antisense Oligonucleotides.
    Takahashi Y; Sato K; Wada T
    J Org Chem; 2022 Mar; 87(6):3895-3909. PubMed ID: 34908418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorothioate modified oligonucleotide-protein interactions.
    Crooke ST; Vickers TA; Liang XH
    Nucleic Acids Res; 2020 Jun; 48(10):5235-5253. PubMed ID: 32356888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solid-Phase Synthesis of Phosphorothioate/Phosphonothioate and Phosphoramidate/Phosphonamidate Oligonucleotides.
    Kostov O; Liboska R; Páv O; Novák P; Rosenberg I
    Molecules; 2019 May; 24(10):. PubMed ID: 31096640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.
    Miller CM; Tanowitz M; Donner AJ; Prakash TP; Swayze EE; Harris EN; Seth PP
    Nucleic Acid Ther; 2018 Jun; 28(3):119-127. PubMed ID: 29425080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A naked antisense oligonucleotide with phosphorothioate linkages is taken up intracellularly more efficiently but functions less effectively.
    Takahashi M; Seki M; Nashimoto M
    Biochem Biophys Res Commun; 2021 Oct; 573():140-144. PubMed ID: 34411896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments.
    Kandimalla ER; Manning A; Zhao Q; Shaw DR; Byrn RA; Sasisekharan V; Agrawal S
    Nucleic Acids Res; 1997 Jan; 25(2):370-8. PubMed ID: 9016567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins.
    Migawa MT; Shen W; Wan WB; Vasquez G; Oestergaard ME; Low A; De Hoyos CL; Gupta R; Murray S; Tanowitz M; Bell M; Nichols JG; Gaus H; Liang XH; Swayze EE; Crooke ST; Seth PP
    Nucleic Acids Res; 2019 Jun; 47(11):5465-5479. PubMed ID: 31034558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterizing the Diastereoisomeric Distribution of Phosphorothioate Oligonucleotides by Metal Ion Complexation Chromatography, In-Series Reversed Phase-Strong Anion Exchange Chromatography, and
    Roussis SG; Cedillo I; Rentel C
    Anal Chem; 2021 Dec; 93(48):16035-16042. PubMed ID: 34813705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carba-LNA-5MeC/A/G/T modified oligos show nucleobase-specific modulation of 3'-exonuclease activity, thermodynamic stability, RNA selectivity, and RNase H elicitation: synthesis and biochemistry.
    Upadhayaya R; Deshpande SG; Li Q; Kardile RA; Sayyed AY; Kshirsagar EK; Salunke RV; Dixit SS; Zhou C; Földesi A; Chattopadhyaya J
    J Org Chem; 2011 Jun; 76(11):4408-31. PubMed ID: 21500818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Versatile and Convenient Synthesis of
    Stulz R; Meuller J; Baždarević D; Wennberg Huldt C; Strömberg R; Andersson S; Dahlén A
    Chembiochem; 2018 Oct; 19(19):2114-2119. PubMed ID: 30062829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1.
    Vickers TA; Rahdar M; Prakash TP; Crooke ST
    Nucleic Acids Res; 2019 Nov; 47(20):10865-10880. PubMed ID: 31495875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
    Gao WY; Han FS; Storm C; Egan W; Cheng YC
    Mol Pharmacol; 1992 Feb; 41(2):223-9. PubMed ID: 1371582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
    Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
    Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2'-Modified oligonucleotides for antisense therapeutics.
    Prakash TP; Bhat B
    Curr Top Med Chem; 2007; 7(7):641-9. PubMed ID: 17430205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides.
    Wang S; Sun H; Tanowitz M; Liang XH; Crooke ST
    Nucleic Acids Res; 2017 May; 45(9):5309-5322. PubMed ID: 28379543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.